Completed a Phase 1a dose-escalation study in China and Australia,respectively.Initiated a multi-center Phase 1b trial in combination with the anti-PD-L1 antibody atezolizumab for advanced solid tumors (including non-small cell lung cancer, gastric cancer, and colorectal cancer etc.,). The aim of clinical trial design to evaluate the synergistic effect, particularly the reversal effect in patients who were resistant to immunotherapy.

Back to List